These results indicated that the increase in TIGIT on PB NK cells together with the increase in CD57 on BM NK cells may explain the subdued NK cell antileukemia capacity and proliferation ability in DN-CML patients. This evidence concerns the gene TIGIT and chronic myelogenous leukemia, BCR-ABL1 positive.